retatrutide clinical trials weight loss results trial safety Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease Retatrutide Severe Obesity Trial Shows – Retatrutide Results: 28.3% – Retatrutide FDA Approval Status 2026:
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23






















